Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E. coli Nissle 1917 suspension for infection prophylaxis in infants
2015-001763-39Phase 3Completed
- Sponsor
- Ardeypharm
- Start
- Jun 2015
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of escherichia coli nissle 1917 in bacterial disease and viral infection, sponsored by Ardeypharm. Primary endpoint: Total number of infections per month during first 24 months. Started Jun 2015; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
bacterial diseaseviral infection
Beyond the preview
Go deeper on 2015-001763-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001763-39.